Clients

Clients

Akeso Therapeutics

Developing a curative therapy for metastatic or refractory/recurrent hematological cancers utilizing T-cells that have been genetically modified via the Sleeping Beauty transposon system (a leading non-viral vector for gene therapy) to express synthetic chimeric antigen receptor (CAR). This has shown promising clinical efficacy in the treatment of acute lymphoblastic leukemia.

Founder: Xianzheng Zhou, Ph.D., M.D.

   
Affina Biotechnologies

Developing a first-in class treatment for late stage ovarian cancer using small hyper-interaction modulators (SHIMs) designed to repair function of mutant p53.

President and CSO: Alexander Vinitsky, Ph.D.
Website: www.affinabio.com 

 

   
MediSprout logo

Telemedicine platform to connect patients to their own doctors using a clinical HIPAA-compliant video communication solution.

Founder and CEO: Samant Virk, M.D.
Website: www.medisprout.com 

 

   
MKM Ventures

Developing cold electrical plasma systems and therapeutics to treat and remove onychomychosis (toenail fungus). Providing targeted destruction of pathogens and abnormal tissue externally avoids damage to surrounding healthy tissue and internal organs.

Co-Founder and CEO: Marc Zemel, S.M., M.B.A.
Website: www.mkmventuresllc.com

   
MOE Medical Devices, LLC  
   
Philips logo

Collaborative computational genomics research activities between Philips Healthcare, NYMC scientists and Westchester Medical Center. 

Website: https://www.philips.com/

   
Retia Medical logo

Has developed a cardiac output monitor which improves patient care by providing members of the critical care team with a more accurate, easy-to-use, and affordable hemodynamic monitor that supports confident, data-based decisions.

Co-Founder and CEO: Marc Zemel, S.M., M.B.A.
Website: www.retiamedical.com 

   
Sapience Therapeutics logo

Advancing novel therapeutics for major unmet medical needs, particularly high-mortality cancers. Sapience’s lead candidate, ST-36, is a peptide-based drug that works as an inhibitor of activating transcription factor 5 (ATF5), which appears relevant to a number of different types of malignancies. ST-36 is designed to promote tumor cell death of glioblastoma multiforme (GBM), the most severe and deadly form of brain cancer.

Founder, President, and CEO: Barry Kappel, Ph.D., M.B.A.
Website: www.sapiencetherapeutics.com 

 

   
SHY Thereapeutics logo

Developing small molecules as anti-cancer therapeutics for unmet medical needs.

Founder and CEO: Yaron Hadari, Ph.D. 

   
SweetDefeat logo


Developed Sweet Defeat, a mint-flavored lozenge that is clinically proven to reduce consumption of and desire for high-sugar foods. The lozenge contains five high-quality, plant-based ingredients, and dissolves on your tongue to help stop sugar cravings within seconds. Sweet Defeat is an effective, safe, and convenient remedy that helps break the sugar-craving cycle so people can make better, healthier food choices without the risks or hassles of traditional supplements, diet pills, or behavior modification programs.

Chief Scientific Officer: Cara Cesario, Ph.D.
Website: www.sweetdefeat.com

 

   
Digi Touch Logo


A digital health company that is developing technology that will empower anyone to measure their blood pressure with clinical accuracy by pressing a button on a smartphone or other mobile device. This technology will dramatically increase the ease and frequency of hypertension monitoring, leading to greater awareness and control of cardiovascular disease.

Founder and CEO: Marc Zemel, S.M., M.B.A.
Website: www.digitouchhealth.com